Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Pfizer Inc. is conducting a clinical study titled ‘Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data.’ The study aims to evaluate the effectiveness of the Pfizer-BioNTech COVID-19 vaccine in preventing post-COVID conditions and to understand the characteristics of patients receiving the vaccine. This research is significant as it leverages state vaccine registries and HealthVerity insurance claims data to gather insights.
The intervention being tested is the Pfizer-BioNTech COVID-19 mRNA vaccine, which is intended to prevent COVID-19 in individuals aged six months and older. The study involves two groups: those vaccinated with the Pfizer-BioNTech XBB dose and those unvaccinated prior to a COVID-19 diagnosis.
This observational study uses a retrospective cohort design to assess vaccine effectiveness and uptake. It does not involve allocation or masking, focusing instead on analyzing existing data to achieve its objectives.
The study began on October 23, 2023, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on July 15, 2025, indicating ongoing progress.
For investors, this study could influence Pfizer’s stock performance by potentially validating the vaccine’s effectiveness, thus boosting investor confidence. It also positions Pfizer competitively in the vaccine market, especially if results are favorable compared to other COVID-19 vaccines.
The study is currently active and not recruiting, with further details accessible on the ClinicalTrials portal.